Absci CEO and founder Sean McClain rings the closing bell on the NASDAQ on Thursday with his team as the Vancouver, Wash.-based biotech company went public. (Absci Photo)
Biotech CEOs tend to have advanced degrees and multiple academic credentials under their belt. But Sean McClain started Absci as a freshly minted grad from the University of Arizona at age 22, living with his parents and working out of a basement lab.
Fast forward a decade later, and McClain is now leading the latest Washington state company to go public.
Absci ended the day with shares up 35% from its opening price on the company’s first day on the NASDAQ. The Vancouver, Wash.-based drug development platform company has a market capitalization of nearly $2 billion.
Absci shares spike 30% in IPO debut, valuing Washington state biotech company at nearly $2B
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Absci shares spike 30% in IPO debut, valuing Washington state biotech company at nearly $2B
geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.
Tech Moves: Edifecs names new CEO; Absci adds execs ahead of IPO; and more
geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.
Vancouver, Wash. biotech company Absci files to go public
July 1, 2021 at 8:36 am
Absci CEO and founder Sean McClain. (Absci Photo)
Absci, a Vancouver, Wash.-based company developing technologies to accelerate the process of drug discovery, announced today that it plans to go public via an IPO. The company’s platform is built to design and generate protein-based drug candidates and help screen them for optimal functioning.
The announcement follows a string of acquisitions and funding rounds for the company. This month the company acquired the synthetic biology company Totient, following its January acquisition of Denovium, a small deep learning startup capable of analyzing the function and behavior of proteins.